IL128900A0 - Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor - Google Patents

Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor

Info

Publication number
IL128900A0
IL128900A0 IL12890097A IL12890097A IL128900A0 IL 128900 A0 IL128900 A0 IL 128900A0 IL 12890097 A IL12890097 A IL 12890097A IL 12890097 A IL12890097 A IL 12890097A IL 128900 A0 IL128900 A0 IL 128900A0
Authority
IL
Israel
Prior art keywords
beta
matrix metalloproteinases
hydroxamic acids
sulfonyl hydroxamic
metalloproteinases inhibitor
Prior art date
Application number
IL12890097A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL128900A0 publication Critical patent/IL128900A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL12890097A 1996-09-27 1997-09-19 Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor IL128900A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2684896P 1996-09-27 1996-09-27
PCT/US1997/016348 WO1998013340A1 (en) 1996-09-27 1997-09-19 β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS

Publications (1)

Publication Number Publication Date
IL128900A0 true IL128900A0 (en) 2000-01-31

Family

ID=21834136

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12890097A IL128900A0 (en) 1996-09-27 1997-09-19 Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor

Country Status (21)

Country Link
US (2) US6235928B1 (https=)
EP (1) EP0929519B1 (https=)
JP (1) JP2001516338A (https=)
KR (1) KR20000048639A (https=)
CN (1) CN1158254C (https=)
AT (1) ATE289590T1 (https=)
AU (1) AU726799B2 (https=)
BR (1) BR9712134A (https=)
CA (1) CA2266368A1 (https=)
CZ (1) CZ92399A3 (https=)
DE (1) DE69732571T2 (https=)
EA (1) EA001460B1 (https=)
ES (1) ES2236829T3 (https=)
HU (1) HUP0000145A3 (https=)
ID (1) ID21897A (https=)
IL (1) IL128900A0 (https=)
NO (1) NO312893B1 (https=)
NZ (1) NZ334729A (https=)
PL (1) PL332509A1 (https=)
UA (1) UA48262C2 (https=)
WO (1) WO1998013340A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
WO1998005635A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
KR20000048639A (ko) 1996-09-27 2000-07-25 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
ATE292622T1 (de) 1997-01-22 2005-04-15 Aventis Pharma Inc Substituierte beta-thiocarbonsäuren
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
NZ337326A (en) * 1997-03-04 2001-05-25 Monsanto Co Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds to inhibit the activity of matrix metalloproteinases
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
KR20010032319A (ko) 1997-11-21 2001-04-16 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제로서 β-술포닐히드록스아민산의 α-히드록시, -아미노 및 -플루오로유도체
AU735929B2 (en) * 1998-01-30 2001-07-19 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
EP0965592A1 (en) 1998-06-18 1999-12-22 F. Hoffmann-La Roche Ag Process for preparing 3-arylsulfur hydroxamic acids
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US6620823B2 (en) * 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) * 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP1966132A2 (en) * 2005-12-15 2008-09-10 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CA2704684A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US8178568B2 (en) * 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
CA2737639A1 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
WO2011037795A1 (en) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB689608A (en) * 1950-04-13 1953-04-01 Basf Ag Improvements in the production of gamma-sulphonyl carboxylic acids
US2659752A (en) * 1951-08-09 1953-11-17 Goodrich Co B F Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
DE4233099A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren
DE4233100A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
PT871439E (pt) * 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
KR20000048639A (ko) 1996-09-27 2000-07-25 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Also Published As

Publication number Publication date
ES2236829T3 (es) 2005-07-16
EP0929519A1 (en) 1999-07-21
EA001460B1 (ru) 2001-04-23
EA199900332A1 (ru) 1999-12-29
DE69732571T2 (de) 2006-01-12
AU726799B2 (en) 2000-11-23
WO1998013340A1 (en) 1998-04-02
CA2266368A1 (en) 1998-04-02
CN1230177A (zh) 1999-09-29
AU4645997A (en) 1998-04-17
US6235928B1 (en) 2001-05-22
NO312893B1 (no) 2002-07-15
HUP0000145A2 (en) 2000-07-28
JP2001516338A (ja) 2001-09-25
BR9712134A (pt) 1999-08-31
HK1022468A1 (en) 2000-08-11
HUP0000145A3 (en) 2001-12-28
KR20000048639A (ko) 2000-07-25
NZ334729A (en) 2001-01-26
UA48262C2 (uk) 2002-08-15
ATE289590T1 (de) 2005-03-15
EP0929519B1 (en) 2005-02-23
ID21897A (id) 1999-08-05
NO991494L (no) 1999-05-26
PL332509A1 (en) 1999-09-13
CN1158254C (zh) 2004-07-21
NO991494D0 (no) 1999-03-26
US5847153A (en) 1998-12-08
CZ92399A3 (cs) 1999-07-14
DE69732571D1 (de) 2005-03-31

Similar Documents

Publication Publication Date Title
IL128900A0 (en) Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor
IL143545A0 (en) Thrombin inhibitors
CA2367017A1 (en) Inhibitors of impdh enzyme
AU2536995A (en) Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
NO20003018L (no) Triazinangiogenese-inhibitorer
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
HK1053831A1 (zh) 作为治疗药物的激酶抑制剂
EA200101085A1 (ru) Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз
AU7401994A (en) Platelet aggregation inhibitors
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
GB9715030D0 (en) Metalloproteinase inhibitors
AU5090393A (en) Platelet aggregation inhibitors
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
TR200003252T2 (tr) Interleukın-1ß dönüştürme enzimi succınamıde inhibitörleri.
AU5710696A (en) Platelet aggregation inhibitors
NO983511L (no) Difenylstilbener som pro-legemidler til COX-2-inhibitorer
ECSP982805A (es) Compuestos de tiourea y benzamida, composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis